21 March 2017Big Pharma

Video interview: Taylor Wessing on SPCs at the CJEU

There have been two significant references on issues that have been "left hanging" by the Court of Justice of the European Union (CJEU) in the last spate of decisions, says Paul England, senior associate at Taylor Wessing, in a video interview with LSIPR.  England discusses the two important references to the CJEU with regard to supplementary protection certificates.  Here he covers the Teva v Gilead Sciences and Abraxis Bioscience references, and talks about the importance of these cases.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
27 November 2025   Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Big Pharma
20 November 2025   A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.
Big Pharma
10 November 2025   According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.